Real-world clinical outcomes of tixagevimab/cilgavimab in the Omicron outbreak in China: baseline characteristics and interim analysis of the CLEAR study

Real-world clinical outcomes of tixagevimab/cilgavimab in the Omicron outbreak in China: baseline characteristics and interim analysis of the CLEAR study

Abstract Purpose This study aimed to investigate the real-world use and clinical outcomes of tixagevimab/cilgavimab in China during the Omicron outbreak in late 2022. Methods This observational, real-world study included patients who received tixagevimab/cilgavimab from July 9 to December 30, 2022,...

Full description

Saved in:
Bibliographic Details
Main Authors: Jianhua You, Haidi Wu, Jiaxin Tian, Jianru Wen, Wenbo Shi, Zhi Wang, Yanjun Du, Hongwei Xu, Hanyu Wei, Xiang Li, Wenyan Kang, Min Zhou, Zhidong Gu, Jieming Qu
Format: Article
Language:English
Published: BMC 2024-10-01
Series:Virology Journal
Subjects:
COVID-19
Omicron variant
Tixagevimab/cilgavimab
Chinese
Online Access:https://doi.org/10.1186/s12985-024-02509-5
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doi.org/10.1186/s12985-024-02509-5

Similar Items